A1 Journal article – refereed

Fixed-Dose Combination of Tafluprost and Timolol in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed-Combination Products




List of Authors: Gábor Holló, Jouni Vuorinen, Juhani Tuominen, Teppo Huttunen, Auli Ropo, Norbert Pfeiffer

Publisher: SPRINGER

Place: NEW YORK; 233 SPRING ST, NEW YORK, NY 10013 USA

Publication year: 2014

Journal: Advances in Therapy

Journal name in source: Advances in Therapy

Journal acronym: Adv.Ther.

Volume number: 31

Issue number: 9

Number of pages: 13

ISSN: 0741-238X

DOI: http://dx.doi.org/10.1007/s12325-014-0151-7


Abstract

A new preservative-free fixed-dose combination of 0.0015% tafluprost, a prostaglandin F-2 alpha analog, and 0.5% timolol (TAF/TIM; Santen Oy, Tampere, Finland), a beta-adrenergic antagonist has recently been developed. The intraocular pressure (IOP) reduction with TAF/TIM in open-angle glaucoma and ocular hypertension is similar to that of other prostaglandin-timolol fixed-combination products. Patients with high IOP responded well to TAF/TIM with reductions of up to 40% (> 13 mmHg) and beyond. Compared to previous controlled and double-masked clinical trials with DuoTrav(A (R)) (Alcon, Fort Worth, USA) and Ganfort(A (R)) (Allergan, Irvine, USA), TAF/TIM caused less superficial ocular side effects and less conjunctival hyperemia. Plausible explanations for the differences in side effects between the fixed-combination products are discussed.



Last updated on 2021-24-06 at 11:30